

Technology Advisory Committee D Interests Register

Topic: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

Publication Date: 19 February 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Will Sullivan	Committee Member	Direct - Financial	<p>Through work at his past employer, Dr Sullivan provided advice and support to Merck Sharp & Dohme regarding pembrolizumab for peri-adjuvant non-small-cell lung cancer. This engagement ended in October 2023.</p> <p>Through work at his past employer, Dr Sullivan also provided advice and support to the same company regarding pembrolizumab for locally advanced, unresectable esophagael/gastroesophagael junction cancer. This engagement ended on 6 November 2023, when his employment at Delta Hat ended.</p>	16/08/2024	It was agreed that Dr Sullivan's declaration would not prevent him from participating in discussions on this appraisal.
Professor David Meads	Committee Member	Direct - Professional	Professor Meads' employer, the University of Leeds, has received funding from BMS, Sanofi and	21/08/2024	It was agreed that Professor Meads' declaration would not

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Celgene for research in an unrelated area.		prevent him from participating in discussions on this appraisal.
Dr Yvonne Summers	Clinical expert	Direct – Financial	Dr Summers conducted paid advisory work for the company (Eli Lilly).	04/09/2024	It was agreed that Dr Summers' declaration would not prevent her from providing expert advice to the committee.